Compass Therapeutics Inc [CMPX] stock is trading at $3.69, up 3.36%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CMPX shares have gain 7.27% over the last week, with a monthly amount glided 25.08%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Leerink Partners upgraded its rating to Outperform on April 02, 2025, and kept the price target unchanged to $6. On February 24, 2025, Guggenheim initiated with a Buy rating and assigned a price target of $12 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $12 on February 19, 2025. D. Boral Capital initiated its recommendation with a Buy and recommended $32 as its price target on December 23, 2024. Leerink Partners downgraded its rating to Market Perform for this stock on November 15, 2024, and downed its price target to $4. In a note dated September 16, 2024, Ladenburg Thalmann upgraded an Buy rating on this stock but restated the target price of $5.
Compass Therapeutics Inc [CMPX] stock has fluctuated between $1.27 and $4.08 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Compass Therapeutics Inc [NASDAQ: CMPX] shares were valued at $3.69 at the most recent close of the market. An investor can expect a potential return of 62.6% based on the average CMPX price forecast.
Analyzing the CMPX fundamentals
Compass Therapeutics Inc [NASDAQ:CMPX] reported sales of 0.00M for the trailing twelve months, which represents a drop of -100.00%. To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -0.53 and Total Capital is -0.66. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Compass Therapeutics Inc’s Current Ratio is 7.66. Further, the Quick Ratio stands at 7.66, while the Cash Ratio is 1.65.
Transactions by insiders
Recent insider trading involved Schuetz Thomas J., CHIEF EXECUTIVE OFFICER, that happened on May 27 ’25 when 10000.0 shares were purchased. Director, GORDON CARL L completed a deal on Apr 09 ’25 to sell 3.57 million shares. Meanwhile, Director ORBIMED ADVISORS LLC sold 3.57 million shares on Apr 09 ’25.
